A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.

Background: Melasma is the commonest cause of facial hypermelanosis in skin type IV-VI. First-line treatment includes a triple combination containing topical corticosteroid and hydroquinone which have side effects on prolonged use. Chemical peels are a second-line management option with the laser be...

Descripción completa

Detalles Bibliográficos
Publicado en:Indian Journal of Dermatology, Venereology & Leprology Vol. 87; no. 1; pp. 51 - 59
Autores principales: Chatterjee, Manas, Neema, Shekhar, Rajput, Gopalsing Rameshsing
Formato: research randomized controlled trial Journal Article
Publicado: Scientific Scholar LLC Jan/Feb2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=154495922&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 154495922
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03786323
        SV4
      jtl: Indian Journal of Dermatology, Venereology & Leprology
      issn: 03786323
      maglogo: N
    pubinfo:
      dt: Jan/Feb2021
      vid: 87
      iid: 1
      pid: 56013
      pub: Scientific Scholar LLC
      place: Pittsford, New York
    artinfo:
      ui:
        154495922
        154495922
        NLM34379946
        154495922
        10.25259/IJDVL_976_18
        NLM34379946
        154495922
      ppf: 51
      ppct: 8
      formats:
      tig:
        atl: A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.
      aug:
        au:
          Chatterjee, Manas
          Neema, Shekhar
          Rajput, Gopalsing Rameshsing
        affil: Department of Dermatology, Venereology and Leprology, Institute of Naval Medicine, INHS Asvini, Mumbai, Maharashtra, India
      sug:
        subj:
          Dermatologic Agents Administration and Dosage
          Sunscreening Agents Administration and Dosage
          Melanosis Drug Therapy
          Male
          Phenyl Ethers Administration and Dosage
          Adult
          Female
          Prospective Studies
          Phenols Administration and Dosage
          Antioxidants Administration and Dosage
          Drug Combinations
          Double-Blind Studies
          Severity of Illness Indices
          Human
          Pilot Studies
          Comparative Studies
          Multicenter Studies
          Randomized Controlled Trials
          Evaluation Research
          Validation Studies
          Short Portable Mental Status Questionnaire
          Arthritis Impact Measurement Scales
          Ferrans and Powers Quality of Life Index
          Adult: 19-44 years
          Male
          Female
      ab: Background: Melasma is the commonest cause of facial hypermelanosis in skin type IV-VI. First-line treatment includes a triple combination containing topical corticosteroid and hydroquinone which have side effects on prolonged use. Chemical peels are a second-line management option with the laser being used in refractory cases, but the worsening of hyperpigmentation in darker skin types can occur following laser therapy. Sunscreen is a must to prevent relapses.Aims and Objectives: (i) To compare the effects of treatment with a proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen) versus sunscreen alone in limiting or reducing, melasma and preventing recurrence as a maintenance regimen after the initial use of triple combination,(ii) to evaluate the safety of the formulation studied, and (iii) to study the improvement of the quality of life of the patients after using the study formulation versus placebo.Methods: It was a prospective double-blinded parallel-group randomized controlled pilot study. A total of 46 subjects were recruited by consecutive sampling methods and randomized to 23 each in case and control groups. The study period was eight months with three phases. Phase 1 constituted the application of triple combination for eight weeks by both groups followed by phase 2 with the case group applying proprietary medicine and the control group applying sunscreen. Phase 3 was a follow-up period to see the sustenance of results in both groups as well as any evidence of relapses. Sunscreen was applied in all three phases.Results: Case group in the study showed improvement in the melasma severity score and mean melanin index as measured by mexameter but it did not attain statistical significance as compared to the control group. The melasma area and severity index score showed a consistent reduction in the case group, whereas it increased in the control group from baseline.Limitations: Small sample size and a short follow-up period of our study were major limitations.Conclusion: The proprietary combination, which has sunscreen as one of its constituents, is more effective in maintaining remission after triple combination without any added inconvenience of application of two separate preparations as compared to sunscreen alone.
      pubtype: Academic Journal
      doctype:
        research
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N